Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwNHL 2014 | 12th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2014: Day 1 meeting highlights

John Gribben, Myron Czuczman, Randy Gascoyne and Wyndham Wilson • 5 Sep 2014
iwNHL 2014
General Non-Hodgkin Lymphoma

Prof John Gribben (Barts Cancer Institute, London, UK) chairs a discussion with Prof Randy Gascoyne (British Columbia Cancer Agency, Vancouver, Canada), Dr Wyndham Wilson (National Cancer Institute, Bethesda, USA) and Dr Myron Czuczman (Roswell Park Cancer Institute, Buffalo, USA) about the highlights from day one of the 12th iwNHL.

More from John Gribben

Investigating the treatment preferences of physicians in R/R follicular lymphoma
2:42
Investigating the treatment preferences of physicians in R/R follicular lymphoma
John Gribben • 9 Dec 2023
Axi-cel in R/R FL: an updated comparison of ZUMA-5 and the SCHOLAR-5 external control cohort
1:20
Axi-cel in R/R FL: an updated comparison of ZUMA-5 and the SCHOLAR-5 external control cohort
John Gribben • 9 Dec 2023
The future of CLL therapy
1:04
The future of CLL therapy
John Gribben • 9 Dec 2023
Novel therapies in NHL: antibody-drug conjugates
Novel therapies in NHL: antibody-drug conjugates
Andrew Davies et al. • 17 Oct 2023

More from Myron Czuczman

Update of targeted or chemotherapy-free therapies in lymphoma
10:51
Update of targeted or chemotherapy-free therapies in lymphoma
John Gribben et al. • 5 Sep 2014
12th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2014: Day 2 meeting highlights
23:19
12th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2014: Day 2 meeting highlights
Anton Hagenbeek et al. • 9 Apr 2015

More from Randy Gascoyne

Lymphoma Microenvironment: biology and therapy (part 2/3)
2:20
Lymphoma Microenvironment: biology and therapy (part 2/3)
John Gribben et al. • 5 Sep 2014
Lymphoma microenvironment: biology and therapy (part 1/3)
5:59
Lymphoma microenvironment: biology and therapy (part 1/3)
John Gribben et al. • 5 Sep 2014
Lymphoma microenvironment: biology and therapy (part 3/3)
7:27
Lymphoma microenvironment: biology and therapy (part 3/3)
John Gribben et al. • 5 Sep 2014
iwNHL 2015 roundtable: Using B-cell biology to inform therapy
9:18
iwNHL 2015 roundtable: Using B-cell biology to inform therapy
Kieron Dunleavy et al. • 3 Oct 2015

More from Wyndham Wilson

Ibrutinib in DLBCL: revelations from further analysis of PHOENIX
4:17
Ibrutinib in DLBCL: revelations from further analysis of PHOENIX
Wyndham Wilson • 2 Jul 2019
Liquid biopsy to measure MRD
1:12
Liquid biopsy to measure MRD
Wyndham Wilson • 2 Jul 2019
ViPOR regimen for R/R B-cell lymphoma
2:30
ViPOR regimen for R/R B-cell lymphoma
Wyndham Wilson • 2 Jul 2019
Liquid biopsy making strides forward in NHL: detection of ctDNA and mutations
2:49
Liquid biopsy making strides forward in NHL: detection of ctDNA and mutations
Wyndham Wilson • 2 Jul 2019

Related Videos

The ethical challenges of AI in hematology: patient communication, trust and regulation
3:12
The ethical challenges of AI in hematology: patient communication, trust and regulation
Adrián Mosquera Orgueira • 24 Sep 2026
The future of AI in hematology: personalized medicine, opportunities and risks
2:30
The future of AI in hematology: personalized medicine, opportunities and risks
Adrián Mosquera Orgueira • 24 Sep 2026
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
5:18
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
Shyam Patel • 13 Oct 2026
The scientific and clinical implications of therapy-related CHIP in oncology
2:43
The scientific and clinical implications of therapy-related CHIP in oncology
Shyam Patel • 13 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals